Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126361091 | 12636109 | 1 | I | 20160726 | 20160809 | 20160809 | EXP | US-CIPLA LTD.-2016US16980 | CIPLA | REEFHUIS J, DEVINE O, FRIEDMAN JM, LOUIK C, HONEIN MA. SPECIFIC SSRIS AND BIRTH DEFECTS: BAYESIAN ANALYSIS TO INTERPRET NEW DATA IN THE CONTEXT OF PREVIOUS REPORTS. BMJ. 2015;350:1 TO 7 | 0.00 | Y | 0.00000 | 20160809 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126361091 | 12636109 | 1 | PS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Transplacental | UNK | 0 | TABLET |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126361091 | 12636109 | CA |
| 126361091 | 12636109 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126361091 | 12636109 | Congenital anomaly | |
| 126361091 | 12636109 | Foetal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |